替诺福韦抗病毒治疗对青岛市中国人群肝切除术后慢性乙型

StephenW

Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality
Zhong Ge 1, Jian Ma 2, Bing Qiao 3, Yanling Wang 4, Haifeng Zhang 3, Wei Gou 3
Affiliations
Affiliations

    1
    Department of Hepatobiliary-Pancreatic Surgery.
    2
    Department of Health Care, Qingdao Municipal Hospital, Qingdao University, Qingdao.
    3
    6th Department, Qingdao No. 6 People's Hospital.
    4
    Dermatological Department, No. 6 People's Hospital, Qingdao, Shandong Province, China.

    PMID: 32769872 DOI: 10.1097/MD.0000000000021454

Abstract

The impact of different antiviral regimen on prognosis of chronic hepatitis B (CHB) related hepatocellular carcinoma (HCC) remains to be explored. A total of 479 CHB-related HCC patients after curative liver resection were enrolled receiving tenofovir (TDF, TDF group) or lamivudine, telbivudine, and entecavir (non-TDF group). Both the overall survival and diseases-free survival were analyzed and compared. A total of 242 patients received TDF treatment and 237 patients received other antiviral regimen. Child-Pugh score, serum α -fetoprotein (AFP) level, total bilirubin level, status of hepatitis B e antigen (HBeAg), and cirrhosis were compared between groups. Kaplan-Meier analysis revealed that patients with TDF treatment had significantly longer overall survival than those of patients with other regimen (P = .015). Similarly, compared with patients with non-TDF treatment, disease-free survival time was longer (P = .042) in those with TDF treatment. Multivariate analysis showed that TDF tr eatment (P = .04), AFP level (P = .03) were significant independent factors associated with overall survival of CHB-related HCC patients. While TDF treatment (P = .04) and serum AFP level (P = .03) were independent factors associated with disease-free survival.Anti-virus treatment with TDF benefits for both overall survival and disease-free survival of CHB-related patients than other Nucleos(t)ide analogues.

StephenW

替诺福韦抗病毒治疗对青岛市中国人群肝切除术后慢性乙型肝炎相关肝癌生存的影响
中革1，剑麻2，冰桥3，王艳玲4，张海峰3，苟沟3
隶属关系
隶属关系

    1个
    肝胆胰外科科。
    2
    青岛大学青岛市立医院卫生部，青岛。
    3
    青岛市第六人民医院第六医院
    4
    山东省青岛市第六人民医院皮肤科

    PMID：32769872 DOI：10.1097 / MD.0000000000021454

抽象

不同抗病毒方案对慢性乙型肝炎（CHB）相关的肝细胞癌（HCC）预后的影响仍有待探索。共有479例治愈性肝切除术后CHB相关的HCC患者入组接受替诺福韦（TDF，TDF组）或拉米夫定，替比夫定和恩替卡韦（非TDF组）。分析并比较了总生存期和无疾病生存期。共有242例患者接受了TDF治疗，而237例患者接受了其他抗病毒治疗。比较两组儿童的Child-Pugh评分，血清α-甲胎蛋白（AFP）水平，总胆红素水平，乙型肝炎e抗原（HBeAg）状况和肝硬化。 Kaplan-Meier分析显示，接受TDF治疗的患者的总生存期明显长于接受其他治疗方案的患者（P = .015）。同样，与未进行TDF治疗的患者相比，接受TDF治疗的患者的无病生存时间更长（P = .042）。多因素分析表明，TDF摄入量（P = .04），AFP水平（P = .03）是与CHB相关HCC患者总生存相关的重要独立因素。 TDF治疗（P = .04）和血清AFP水平（P = .03）是与无病生存相关的独立因素。TDF抗病毒治疗对CHB相关患者的总体生存和无病生存都有好处比其他Nucleos（t）ide类似物。

StephenW

https://doi.org/10.1097/md.0000000000021454